Hemab Doses First Participant in HMB-003 Phase 1
CAMBRIDGE, Mass. and COPENHAGEN, Denmark — September 17, 2026 Hemab Therapeutics announced that the first healthy volunteer has been...
Phase 1
Advertisement
Avacta Achieves Clinical Proof of Mechanism for AVA6103
LONDON and PHILADELPHIA — September 16, 2026 Avacta Therapeutics announced clinical proof of mechanism for AVA6103, its next-generation controlled-release...
Aethlon Medical Merges With North Immunology for NOR-101
San Diego, California, and Austin, Texas, September 17, 2026 Aethlon Medical, Inc. and North Immunology, Inc. have announced a...
Kestrel Therapeutics Gains FDA Fast Track for KST-6051
WATERTOWN, Mass. — September 15, 2026 Kestrel Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has...
Nanobiotix Advances JNJ-1900 in Recurrent NSCLC
PARIS, France and CAMBRIDGE, Mass. — September 14, 2026 Nanobiotix announced complete Phase 1 safety and efficacy findings for...
Advertisements
Syntis Bio Advances Oral SYNT-101 Toward Phase 2
BOSTON — September 15, 2026 Syntis Bio, Inc. announced results from the 28-day multiple-ascending-dose (MAD) portion of its Phase...
One04 Therapeutics Launches With CPV-104 Clinical Expansion
FREIBURG, Germany — September 15, 2026 One04 Therapeutics GmbH & Co. KG announced its launch as a clinical-stage biopharmaceutical...
Santa Ana Bio Advances SAB01 Into Phase 1
ALAMEDA, Calif. — September 14, 2026 Santa Ana Bio announced that the first cohort has been dosed in the...
Agomab Advances AGMB-447 Into Phase 2 for IPF
ANTWERP, Belgium — September 14, 2026 Agomab Therapeutics NV announced positive Phase 1 results for AGMB-447, an investigational inhaled,...
Clearmind Medicine Advances CMND-100 Into AUD Clinical Trial
VANCOUVER, Canada — September 11, 2026 Clearmind Medicine Inc. announced that the first patients with Alcohol Use Disorder (AUD)...
Advertisement
